Alley Co LLC grew its position in shares of Danaher Corporation (NYSE:DHR) by 3.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,229 shares of the conglomerate’s stock after buying an additional 828 shares during the quarter. Alley Co LLC’s holdings in Danaher Corporation were worth $2,213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pictet Asset Management Ltd. lifted its holdings in shares of Danaher Corporation by 6.8% during the 2nd quarter. Pictet Asset Management Ltd. now owns 2,679,003 shares of the conglomerate’s stock valued at $227,555,000 after buying an additional 169,669 shares during the period. Palisade Capital Management LLC NJ lifted its holdings in shares of Danaher Corporation by 13.3% during the 2nd quarter. Palisade Capital Management LLC NJ now owns 211,569 shares of the conglomerate’s stock valued at $17,854,000 after buying an additional 24,894 shares during the period. Endurance Wealth Management Inc. lifted its holdings in shares of Danaher Corporation by 4.2% during the 2nd quarter. Endurance Wealth Management Inc. now owns 81,337 shares of the conglomerate’s stock valued at $6,864,000 after buying an additional 3,269 shares during the period. Davis R M Inc. lifted its holdings in shares of Danaher Corporation by 1.7% during the 2nd quarter. Davis R M Inc. now owns 402,619 shares of the conglomerate’s stock valued at $33,977,000 after buying an additional 6,918 shares during the period. Finally, Norris Perne & French LLP MI lifted its holdings in shares of Danaher Corporation by 4.9% during the 2nd quarter. Norris Perne & French LLP MI now owns 46,069 shares of the conglomerate’s stock valued at $3,888,000 after buying an additional 2,167 shares during the period. 75.75% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This news story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/15/danaher-corporation-dhr-shares-bought-by-alley-co-llc.html.
In other Danaher Corporation news, Director Linda P. Hefner sold 10,578 shares of the stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $83.03, for a total value of $878,291.34. Following the completion of the sale, the director now owns 42,151 shares in the company, valued at approximately $3,499,797.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider William King sold 43,688 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $82.86, for a total transaction of $3,619,987.68. Following the completion of the sale, the insider now owns 45,748 shares of the company’s stock, valued at approximately $3,790,679.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,496 shares of company stock valued at $5,916,223. 12.20% of the stock is owned by insiders.
Several research firms have recently weighed in on DHR. BidaskClub cut Danaher Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Zacks Investment Research cut Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. Citigroup Inc. set a $96.00 target price on Danaher Corporation and gave the stock a “buy” rating in a report on Friday, July 21st. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $88.00 target price on shares of Danaher Corporation in a report on Wednesday, July 12th. Finally, Janney Montgomery Scott cut Danaher Corporation from a “buy” rating to a “neutral” rating in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Danaher Corporation presently has an average rating of “Buy” and a consensus target price of $92.72.
Danaher Corporation (NYSE:DHR) opened at 88.44 on Friday. The stock’s 50 day moving average price is $82.44 and its 200-day moving average price is $84.21. The stock has a market cap of $61.44 billion, a price-to-earnings ratio of 28.23 and a beta of 1.03. Danaher Corporation has a 12 month low of $75.71 and a 12 month high of $88.48.
Danaher Corporation (NYSE:DHR) last released its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The firm had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.50 billion. During the same quarter in the prior year, the firm earned $0.90 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities analysts expect that Danaher Corporation will post $3.95 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 29th will be issued a $0.14 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.63%. Danaher Corporation’s payout ratio is 17.83%.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.